The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Patterns-of-failure studies suggest that in metastatic non-small-cell lung cancer (NSCLC) sites of gross disease at presentation are the first to progress when treated with chemotherapy. This knowledge has led to increased adoption of local ablative radiation therapy in patients with stage IV NSCLC, though prospective randomized evidence is limited. OBJECTIVE: To determine if intervening with noninvasive stereotactic ablative radiotherapy (SAbR) prior to maintenance chemotherapy in patients with non-progressive limited metastatic NSCLC after induction therapy led to significant improvements in progression-free survival (PFS). DESIGN, SETTING, AND PARTICIPANTS: This is a single-institution randomized phase 2 study of maintenance chemotherapy alone vs SAbR followed by maintenance chemotherapy for patients with limited metastatic NSCLC (primary plus up to 5 metastatic sites) whose tumors did not possess EGFR-targetable or ALK-targetable mutations but did achieve a partial response or stable disease after induction chemotherapy. INTERVENTIONS: Maintenance chemotherapy or SAbR to all sites of gross disease (including SAbR or hypofractionated radiation to the primary) followed by maintenance chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was PFS; secondary end points included toxic effects, local and distant tumor control, patterns of failure, and overall survival. RESULTS: A total of 29 patients (9 women and 20 men) were enrolled; 14 patients (median [range] age, 63.5 [51.0-78.0] years) were allocated to the SAbR-plus-maintenance chemotherapy arm, and 15 patients (median [range] age, 70.0 [51.0-79.0] years) were allocated to the maintenance chemotherapy-alone arm. The trial was stopped to accrual early after an interim analysis found a significant improvement in PFS in the SAbR-plus-maintenance chemotherapy arm of 9.7 months vs 3.5 months in the maintenance chemotherapy-alone arm (P = .01). Toxic effects were similar in both arms. There were no in-field failures with fewer overall recurrences in the SAbR arm while those patients receiving maintenance therapy alone had progression at existing sites of disease and distantly. CONCLUSIONS AND RELEVANCE: Consolidative SAbR prior to maintenance chemotherapy appeared beneficial, nearly tripling PFS in patients with limited metastatic NSCLC compared with maintenance chemotherapy alone, with no difference in toxic effects. The irradiation prevented local failures in original disease, the most likely sites of first recurrence. Furthermore, PFS for patients with limited metastatic disease appeared similar to those patients with a greater metastatic burden, further arguing for the potential benefits of local therapy in limited metastatic settings. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02045446.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
Self-citationImmunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Self-citationLong-term results of lung metastasectomy: Prognostic analyses based on 5206 cases
Pastorino, U., Buyse, M., Friedel, G., Ginsberg, R. J., Girard, P., Goldstraw, P., Johnston, M., McCormack, P., Pass, H., & Putnam, J. B. (1997) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(97)70397-0 · Cited by 1,529
Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases
Choti, M. A., Sitzmann, J. V., Tiburi, M. F., Sumetchotimetha, W., Rangsin, R., Schulick, R. D., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00002 · Cited by 1,454
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186 · cited 1×
“The median (range) number of maintenance chemotherapy cycles was 3 (115) for the maintenance-only group and 5 (3-19) for the SAbR group; individual patient treatment information is included in Tables 2 and 3.”
BackgroundCiuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091
Gomez, D. R., Blumenschein, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30532-0 · Cited by 1,086
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
Rusthoven, K. E., Kavanagh, B. D., Burri, S. H., Chen, C., Cardenes, H., Chidel, M. A., Pugh, T. J., Kane, M., Gaspar, L. E., & Schefter, T. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6386 · Cited by 1,082
Weichselbaum, R. R., & Hellman, S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.44 · Cited by 945
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934
The New Lung Cancer Staging System
Detterbeck, F. C., Boffa, D. J., & Tanoue, L. T. (2009) · Chest · doi:10.1378/chest.08-0978 · Cited by 817
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
Rusthoven, K. E., Kavanagh, B. D., Cardenes, H., Stieber, V. W., Burri, S. H., Feigenberg, S. J., Chidel, M. A., Pugh, T. J., Franklin, W., Kane, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6329 · Cited by 805
Repeated Significance Tests on Accumulating Data
Armitage, P., McPherson, C. K., & Rowe, B. C. (1969) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2343787 · Cited by 761
Potters, L., Kavanagh, B., Galvin, J. M., Hevezi, J. M., Janjan, N. A., Larson, D. A., Mehta, M. P., Ryu, S., Steinberg, M., Timmerman, R., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.042 · Cited by 664
Self-citationMinagawa, M., Makuuchi, M., Torzilli, G., Takayama, T., Kawasaki, S., Kosuge, T., Yamamoto, J., & Imamura, H. (2000) · Annals of Surgery · doi:10.1097/00000658-200004000-00006 · Cited by 663
Park, C., Papiez, L., Zhang, S., Story, M., & Timmerman, R. D. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.10.059 · Cited by 651
Self-citationPaz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70063-3 · Cited by 610 · cited 1×
“The median (range) number of maintenance chemotherapy cycles was 3 (115) for the maintenance-only group and 5 (3-19) for the SAbR group; individual patient treatment information is included in Tables 2 and 3.”
BackgroundAn Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation Oncology
Timmerman, R. D. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.04.001 · Cited by 478
Self-citationTumor size, sensitivity to therapy, and design of treatment schedules.
Norton, L., & Simon, R. M. (1977) · PubMed · Cited by 447
Milano, M. T., Katz, A. W., Zhang, H., & Okunieff, P. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.08.036 · Cited by 439
Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., Congedo, M. T., Gomez, D. R., Wright, G. M., Melloni, G., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.04.003 · Cited by 435
Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., Chen, R., Hristova-Kazmierski, M., Treat, J., Obasaju, C. K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1405 · Cited by 418
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Ramalingam, S., & Belani, C. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s1-5 · Cited by 333
Salama, J. K., Hasselle, M. D., Chmura, S. J., Malik, R., Mehta, N., Yenice, K. M., Villaflor, V. M., Stadler, W. M., Hoffman, P. C., Cohen, E. E. W., et al. (2012) · Cancer · doi:10.1002/cncr.26611 · Cited by 320
Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N., Ciuleanu, T., Cucevic, B., Gyurkovits, K., Ulsperger, E., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.006 · Cited by 320
Iyengar, P., Kavanagh, B. D., Wardak, Z., Smith, I., Ahn, C., Gerber, D. E., Dowell, J., Hughes, R., Abdulrahman, R., Camidge, D. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7412 · Cited by 286
Self-citationDe Ruysscher, D., Wanders, R., van Baardwijk, A., Dingemans, A.-M. C., Reymen, B., Houben, R., Bootsma, G., Pitz, C., van Eijsden, L., Geraedts, W., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318262caf6 · Cited by 283
Laparoscopic Adrenalectomy for Isolated Adrenal Metastasis
Strong, V. E., D’Angelica, M., Tang, L., Prete, F., Gönen, M., Coit, D., Touijer, K. A., Fong, Y., & Brennan, M. F. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9520-7 · Cited by 225
Interim Analyses in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners
Geller, N. L., & Pocock, S. J. (1987) · Biometrics · doi:10.2307/2531962 · Cited by 200
Treatment of Stage IV Non-small Cell Lung Cancer
Socinski, M. A., Evans, T., Gettinger, S., Hensing, T. A., VanDam Sequist, L., Ireland, B., & Stinchcombe, T. E. (2013) · Chest · doi:10.1378/chest.12-2361 · Cited by 189
Collen, C., Christian, N., Schallier, D., Meysman, M., Duchateau, M., Storme, G., & De Ridder, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu370 · Cited by 171
Rusthoven, K. E., Hammerman, S. F., Kavanagh, B. D., Birtwhistle, M. J., Stares, M., & Camidge, D. R. (2009) · Acta Oncologica · doi:10.1080/02841860802662722 · Cited by 165
Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases
Lewis, S. L., Porceddu, S. V., Nakamura, N., Palma, D. A., Lo, S. S.-M., Hoskin, P., Moghanaki, D. M., Chmura, S. J., & Salama, J. K. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000169 · Cited by 151
Mehta, N. J., Mauer, A. M., Hellmän, S., et al. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.6.1677 · Cited by 115
Hasselle, M. D., Haraf, D. J., Rusthoven, K. E., Golden, D. W., Salgia, R., Villaflor, V. M., Shah, N., Hoffman, P. C., Chmura, S. J., Connell, P. P., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824166a5 · Cited by 101
Downey, R. J., Ng, K., Kris, M. G., Bains, M. S., Miller, V. A., Heelan, R. T., Bilsky, M. H., Ginsberg, R. J., & Rusch, V. W. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00183-6 · Cited by 94
Repeated Significance Tests on Accumulating Data when the Null Hypothesis is not True
McPherson, C. K., & Armitage, P. (1971) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2343971 · Cited by 88
Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer
Cheruvu, P., Metcalfe, S. K., Metcalfe, J. D., Chen, Y., Okunieff, P. G., & Milano, M. T. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-80 · Cited by 74
Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis
Behera, M., Owonikoko, T. K., Chen, Z., Kono, S. A., Khuri, F. R., Belani, C. P., & Ramalingam, S. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.019 · Cited by 56
Baseline tumour measurements predict survival in advanced non-small cell lung cancer
Gerber, D. E., Dahlberg, S. E., Sandler, A. B., Ahn, D. H., Schiller, J. H., Brahmer, J. R., & Johnson, D. H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.472 · Cited by 42
Self-citationThird CECOG consensus on the systemic treatment of non-small-cell lung cancer
Brodowicz, T., Ciuleanu, T., Crawford, J., Filipits, M., Fischer, J. R., Georgoulias, V., Gridelli, C., Hirsch, F. R., Jassem, J., Kosmidis, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr381 · Cited by 27
Xanthopoulos, E. P., Handorf, E. R., Simone, C. B., Grover, S., Fernandes, A., Sharma, S., Corradetti, M. N., Evans, T. L., Langer, C. J., Mitra, N., et al. (2015) · Practical Radiation Oncology · doi:10.1016/j.prro.2014.11.006 · Cited by 20
Maintenance Therapy for Advanced Lung Cancer: Who, What, and When?
Gerber, D. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5201 · Cited by 13
Self-citation
Cited by
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“The second study randomised patients with 5 metastatic sites between maintenance ChT alone versus SABR followed by maintenance ChT (n1⁄4 29) [312].”
BackgroundPalma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00818 · Cited by 1,300
Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00201 · Cited by 1,283
Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0147 · Cited by 1,159
Metadata
- Authors
- Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Westover, K. D., Pulipparacharuvil, S., Choy, H., & Timmerman, R. D.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-01-11
- Volume
- 4
- Issue
- 1
- Pages
- e173501
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2761351587
- Cited by
- 1,047
- References
- 50
- FWCI
- 59.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.